Neil Averitt commentary: Insulin cases need a sharper focus
Hard cases are notorious for making bad law. But sometimes the easy and obvious cases can make bad law, too. Something like this seems to be going on with insulin pricing....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch